These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 12107109)

  • 21. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival.
    De Vita G; Melillo RM; Carlomagno F; Visconti R; Castellone MD; Bellacosa A; Billaud M; Fusco A; Tsichlis PN; Santoro M
    Cancer Res; 2000 Jul; 60(14):3727-31. PubMed ID: 10919641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.
    Murakami H; Iwashita T; Asai N; Shimono Y; Iwata Y; Kawai K; Takahashi M
    Biochem Biophys Res Commun; 1999 Aug; 262(1):68-75. PubMed ID: 10448070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sympathoadrenal hyperplasia causes renal malformations in Ret(MEN2B)-transgenic mice.
    Gestblom C; Sweetser DA; Doggett B; Kapur RP
    Am J Pathol; 1999 Dec; 155(6):2167-79. PubMed ID: 10595945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A potential pathogenetic mechanism for multiple endocrine neoplasia type 2 syndromes involves ret-induced impairment of terminal differentiation of neuroepithelial cells.
    Califano D; D'Alessio A; Colucci-D'Amato GL; De Vita G; Monaco C; Santelli G; Di Fiore PP; Vecchio G; Fusco A; Santoro M; de Franciscis V
    Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7933-7. PubMed ID: 8755580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation analysis of glial cell line-derived neurotrophic factor, a ligand for an RET/coreceptor complex, in multiple endocrine neoplasia type 2 and sporadic neuroendocrine tumors.
    Marsh DJ; Zheng Z; Arnold A; Andrew SD; Learoyd D; Frilling A; Komminoth P; Neumann HP; Ponder BA; Rollins BJ; Shapiro GI; Robinson BG; Mulligan LM; Eng C
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3025-8. PubMed ID: 9284737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
    Kameyama K; Okinaga H; Takami H
    Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [From gene to disease; from the RET gene to multiple endocrine neoplasia types 2A and 2B, sporadic and familial medullary thyroid carcinoma, Hirschsprung disease and papillary thyroid carcinoma].
    Hofstra RM; van der Luijt RB; Lips CJ
    Ned Tijdschr Geneeskd; 2001 Nov; 145(46):2217-21. PubMed ID: 11757244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential.
    Cirafici AM; Salvatore G; De Vita G; Carlomagno F; Dathan NA; Visconti R; Melillo RM; Fusco A; Santoro M
    Endocrinology; 1997 Apr; 138(4):1450-5. PubMed ID: 9075701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function?
    Takahashi M; Iwashita T; Santoro M; Lyonnet S; Lenoir GM; Billaud M
    Hum Mutat; 1999; 13(4):331-6. PubMed ID: 10220148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice.
    Hasegawa T; Enomoto A; Kato T; Kawai K; Miyamoto R; Jijiwa M; Ichihara M; Ishida M; Asai N; Murakumo Y; Ohara K; Niwa Y; Goto H; Takahashi M
    Oncogene; 2008 Sep; 27(43):5684-95. PubMed ID: 18542059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.
    Vidal M; Wells S; Ryan A; Cagan R
    Cancer Res; 2005 May; 65(9):3538-41. PubMed ID: 15867345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.
    Carlomagno F; Salvatore G; Cirafici AM; De Vita G; Melillo RM; de Franciscis V; Billaud M; Fusco A; Santoro M
    Cancer Res; 1997 Feb; 57(3):391-5. PubMed ID: 9012462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations.
    Takahashi M; Asai N; Iwashita T; Murakami H; Ito S
    J Intern Med; 1998 Jun; 243(6):509-13. PubMed ID: 9681851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prophylactic total thyroidectomy in children and adolescents with genetic mutations in the RET-protooncogene].
    Spinelli C; Puccini M; Bertocchini A; Lima M; Pacini F; Miccoli P
    Pediatr Med Chir; 2002; 24(1):53-7. PubMed ID: 11938683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ganglioneuromas and renal anomalies are induced by activated RET(MEN2B) in transgenic mice.
    Sweetser DA; Froelick GJ; Matsumoto AM; Kafer KE; Marck B; Palmiter RD; Kapur RP
    Oncogene; 1999 Jan; 18(4):877-86. PubMed ID: 10023663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of BMK1 via tyrosine 1062 in RET by GDNF and MEN2A mutation.
    Hayashi Y; Iwashita T; Murakamai H; Kato Y; Kawai K; Kurokawa K; Tohnai I; Ueda M; Takahashi M
    Biochem Biophys Res Commun; 2001 Mar; 281(3):682-9. PubMed ID: 11237712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
    Sansó G; Domené HM; Iorcansky S; Barontini M
    Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
    Kambouris M; Jackson CE; Feldman GL
    Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ligand stimulation of a Ret chimeric receptor carrying the activating mutation responsible for the multiple endocrine neoplasia type 2B.
    Rizzo C; Califano D; Colucci-D'Amato GL; De Vita G; D'Alessio A; Dathan NA; Fusco A; Monaco C; Santelli G; Vecchio G; Santoro M; de Franciscis V
    J Biol Chem; 1996 Nov; 271(46):29497-501. PubMed ID: 8910618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.